SYNTHETIC DEMONSTRATION — no real student or patient. Not a medical device.

gi-specialist

NASH Liver Disease Treatment Options (2024 Guide)

NASH (nonalcoholic steatohepatitis) treatment centers on meaningful weight loss and controlling metabolic risk factors like diabetes and high triglycerides. The FDA approved the first drug specifically for NASH with liver fibrosis in 2024. A gastroenterologist or hepatologist should guide the overall care plan, which may also include weight-loss medications.

Talk to a clinician

Gale can match you with a licensed clinician for a visit.

Find care →

What is the difference between NAFLD and NASH?

Nonalcoholic fatty liver disease (NAFLD) — now increasingly called metabolic dysfunction-associated steatotic liver disease, or MASLD — is an umbrella term for excess fat in the liver unrelated to heavy alcohol use 12. Simple fatty liver (steatosis) is one end of the spectrum. NASH is the more serious form: fat plus inflammation plus liver cell injury. Left untreated, NASH can progress to fibrosis (scarring), cirrhosis, liver failure, and an elevated risk of liver cancer. Not everyone with NAFLD develops NASH, but there is no reliable way to predict who will based on symptoms alone, which is why liver biopsy has historically been the gold-standard diagnostic step — though noninvasive biomarkers and imaging-based tests are increasingly used to avoid biopsy in appropriate patients 1.

What does lifestyle treatment for NASH involve?

Lifestyle change remains the foundation of NASH treatment at every stage. The key elements are:

  • Weight loss: Losing 7–10% of body weight is associated with improvements in liver inflammation and, with greater loss, in fibrosis. The improvement tends to track with how much weight is lost and sustained.
  • Dietary pattern: Diets lower in refined carbohydrates, added sugars (particularly fructose), and saturated fat — broadly consistent with a Mediterranean eating pattern — are associated with improved liver fat.
  • Physical activity: Both aerobic exercise and resistance training independently improve liver fat, even before significant weight loss.
  • Alcohol: Alcohol worsens any form of fatty liver disease and should be minimized or eliminated.
  • Metabolic risk factors: Treating type 2 diabetes, high triglycerides, and high blood pressure reduces the metabolic burden on the liver. Certain diabetes medications — including GLP-1 receptor agonists and SGLT-2 inhibitors — appear to have beneficial effects on liver fat, though the exact role in NASH management is still evolving.

Are there medications specifically approved for NASH?

For most of its history, NASH had no FDA-approved pharmacotherapy. That changed in 2024, when resmetirom (brand name Rezdiffra) became the first drug specifically approved for adults with noncirrhotic NASH with moderate-to-advanced liver fibrosis (stages F2–F3) in combination with diet and exercise. Resmetirom is a thyroid hormone receptor-beta agonist that targets liver metabolism.

Other medications studied in NASH include obeticholic acid (an FXR agonist) and lanifibranor; their regulatory status and available evidence continue to evolve. Because the field is moving rapidly, an up-to-date conversation with a gastroenterologist or hepatologist who specializes in liver disease is the best way to understand current approved options and any active clinical trials that might be appropriate for your situation 2.

It is important to note that no supplement — including vitamin E (used in some earlier research), milk thistle, or others — has FDA approval for NASH treatment. Their evidence base is limited and their use should be discussed with a clinician.

What about weight-loss medications for NASH?

GLP-1 receptor agonists like semaglutide have shown reductions in liver fat and inflammation in clinical trials of people with NASH and obesity or type 2 diabetes, and this area of research is active. These agents are approved for obesity or diabetes management, not specifically for NASH, so using them in the context of NASH would be discussed as part of a broader metabolic treatment plan. If you have both NASH and significant obesity, a clinician may consider one of these medications as part of an integrated approach.

When should I see a specialist?

A gastroenterologist or hepatologist (liver specialist) is the right specialist for NASH. You should seek a referral when:

  • NASH has been confirmed or is suspected based on imaging or liver tests
  • Fibrosis (scarring) is present or suspected
  • Liver enzymes remain elevated despite lifestyle changes
  • You have cirrhosis or are being evaluated for it
  • You want to know whether a new approved medication or a clinical trial is appropriate

Clinicians often use a combination of blood-based scores, imaging (such as FibroScan), and sometimes liver biopsy to assess the severity of disease before recommending a treatment path 1. Gale can help you prepare for that specialist visit and coordinate a referral.

Common questions

Can NASH be reversed?

In earlier stages, NASH can improve and even resolve with sustained weight loss and metabolic control. Advanced fibrosis is harder to reverse, which is why early intervention and specialist follow-up matter.

Is NASH the same as MASLD?

They largely overlap. MASLD (metabolic dysfunction-associated steatotic liver disease) is the newer preferred term replacing NAFLD, and MASH (metabolic dysfunction-associated steatohepatitis) is the corresponding term for what was called NASH. Both terms may appear in your records depending on when they were written.

Do I need a liver biopsy to diagnose NASH?

Liver biopsy has been the traditional gold standard, but noninvasive tests — including blood-based biomarker panels and elastography imaging — are increasingly used to assess liver fat and fibrosis without a biopsy. Your gastroenterologist or hepatologist will advise on the best approach for your situation.

Does alcohol make NASH worse?

Yes. Even moderate alcohol use adds stress to a liver already dealing with fat and inflammation. Most liver specialists advise people with NASH to minimize or eliminate alcohol.

Talk to a clinician

Gale can match you with a licensed clinician for a visit.

Find care →

When to seek care promptly

  • —Yellowing of the skin or whites of the eyes (jaundice)
  • —Abdominal swelling or significant bloating that is new or worsening
  • —Confusion or difficulty thinking clearly (possible hepatic encephalopathy)
  • —Vomiting blood or passing very dark, tarry stools
  • —Severe fatigue or loss of appetite that is rapidly worsening

If you experience vomiting blood, black tarry stools, or sudden confusion, call 911 or go to the nearest emergency room.

This article provides general health education and does not constitute personalized medical advice, a diagnosis, or a treatment recommendation. Treatment decisions for NASH should be made with a gastroenterologist or hepatologist who can evaluate your individual test results and medical history.

References

  1. 1.Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ (2023). AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. doi:10.1053/j.gastro.2023.06.013 ✓Noninvasive biomarkers and their role in NAFLD/NASH diagnosis and staging
  2. 2.Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME (2024). Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. doi:10.1097/HEP.0000000000000670 ✓MASLD nomenclature update and current AASLD guidance on NASH/NAFLD management
  3. 3.National Institute of Diabetes and Digestive and Kidney Diseases (2023). Definition & Facts of NAFLD & NASH. NIDDK. link ✓Patient-facing overview of NAFLD and NASH spectrum, risk factors, and definitions

3 sources, numbered by first appearance. General health information, not medical advice — synthetic demonstration content.